Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of April 2023, specifically dated April 20, 2023. The report serves to disseminate a press release regarding clinical study results for the Company's ProSense System.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The primary material event disclosed is the publication of results from an endometriosis cryoablation study utilizing the Company's ProSense System. The study demonstrated an efficacy rate of 92.8% in avoiding secondary surgery.
Guidance, Outlook, and Risks
The filing incorporates specific paragraphs from the press release into the Company's Registration Statements on Form F-3 and Form S-8. No specific financial guidance, forward-looking outlook, or new risk factors are detailed within the text of this Form 6-K.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) to understand the study design and patient population.
- Confirm the clinical significance of the 92.8% efficacy rate in avoiding secondary surgery for endometriosis.
- Review the Company's Registration Statements (File Nos. 333-267272, 333-258660, 333-270982, 333-264578, and 333-262620) to see how the incorporated paragraphs affect ongoing capital raising efforts.